Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
JULIO GRANADOS MONTIEL
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07567378CT.gov CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | — | Not Yet Recruiting | — | — | — |
NCT06606821CT.gov The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Coronary Artery Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tirzepatide (this asset) | JULIO GRANADOS MONTIEL | Approved | BB · 65 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Ezetimibe | Canadian Collaborative Research Network | P4 | BBB |
| Simvastatin | University of Washington | P4 | BBB |
| Ranolazine | OBS Pakistan | P4 | BBB |
| Rivaroxaban | Sheffield Teaching Hospitals NHS Foundation Trust | P4 | BBB |
| Pitavastatin | Yokohama City University Medical Center | P4 | BBB |
| Clopidogrel | Beijing Tiantan Hospital | P4 | BB |
| Danhong | China Academy of Chinese Medical Sciences | P4 | BB |
+40 more in the Coronary Artery Disorder cohort
Other indications for Tirzepatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 1 Diabetes Mellitus | — | P4 | BBB · 78 |
| Psoriatic Arthritis | — | P4 | BBB · 74 |
| Diastolic Heart Failure | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tirzepatide in Coronary Artery Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tirzepatide-coronary-artery-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →